explore -WSS

explore

author：hotspot 2025-10-01 23:38:54 - browse：4

Stock illustration of computer and medication — Adobe

Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital treatments will find a new life as part of PursueCare, which provides online addiction care and mental health counseling.

PursueCare today announced it had raised a $20 million Series B round and that it had acquired Pear’s portfolio of apps that treat people with addiction problems. PursueCare’s CEO Nick Mercadante told STAT the company hopes to develop the market for the treatments where Pear could not, by taking advantage of its access to patients and insurers.

“My view of digital therapeutics is that those point solutions really need a horse to draw the carriage,” he said. “You need a willing and capable service provider that says we’re going to make this a big part of real world care and… then show the health plans how it can save them money in the real world without extra thinking.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Why don't Americans have at

WSS

Doctors on social media are being harassed and cyberbullied

Congress might make insulin pumps more accessible to the blind

How the drug

Intellia plays down concerns on accidental germline transmission

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Roche's accidental data boosts hopes for anti

focus

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Amylyx, Aurinia, and IQVIA

The high cost of giving birth even with insurance

Roche's accidental data boosts hopes for anti

Anesthesiologist group: stop taking Ozempic before surgery

Republicans love RFK Jr. What's that tell us about health in 2024?

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

The high cost of giving birth even with insurance

Hospital at home shows how to bring innovation to health care

hotspot

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Trans patients at the end of life deserve respect and dignity

Long Covid research funding gets a major boost from NIH

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Report cites 'urgent' need to recruit more diverse clinical trial participants

entertainment

focus

explore

explore